Netherlands Cancer Institute, Department of Epidemiology and Biostatistics, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands.
BMJ. 2012 Sep 6;345:e5660. doi: 10.1136/bmj.e5660.
To estimate the risk of breast cancer associated with diagnostic radiation in carriers of BRCA1/2 mutations.
Retrospective cohort study (GENE-RAD-RISK).
Three nationwide studies (GENEPSO, EMBRACE, HEBON) in France, United Kingdom, and the Netherlands,
1993 female carriers of BRCA1/2 mutations recruited in 2006-09.
Risk of breast cancer estimated with a weighted Cox proportional hazards model with a time dependent individually estimated cumulative breast dose, based on nominal estimates of organ dose and frequency of self reported diagnostic procedures. To correct for potential survival bias, the analysis excluded carriers who were diagnosed more than five years before completion of the study questionnaire.
In carriers of BRCA1/2 mutations any exposure to diagnostic radiation before the age of 30 was associated with an increased risk of breast cancer (hazard ratio 1.90, 95% confidence interval 1.20 to 3.00), with a dose-response pattern. The risks by quarter of estimated cumulative dose <0.0020 Gy, ≥ 0.0020-0.0065 Gy, ≥ 0.0066-0.0173 Gy, and ≥ 0.0174 Gy were 1.63 (0.96 to 2.77), 1.78 (0.88 to 3.58), 1.75 (0.72 to 4.25), and 3.84 (1.67 to 8.79), respectively. Analyses on the different types of diagnostic procedures showed a pattern of increasing risk with increasing number of radiographs before age 20 and before age 30 compared with no exposure. A history of mammography before age 30 was also associated with an increased risk of breast cancer (hazard ratio 1.43, 0.85 to 2.40). Sensitivity analysis showed that this finding was not caused by confounding by indication of family history.
In this large European study among carriers of BRCA1/2 mutations, exposure to diagnostic radiation before age 30 was associated with an increased risk of breast cancer at dose levels considerably lower than those at which increases have been found in other cohorts exposed to radiation. The results of this study support the use of non-ionising radiation imaging techniques (such as magnetic resonance imaging) as the main tool for surveillance in young women with BRCA1/2 mutations.
评估携带 BRCA1/2 突变的女性中诊断性辐射相关乳腺癌的风险。
回顾性队列研究(GENE-RAD-RISK)。
法国、英国和荷兰的三项全国性研究(GENEPSO、EMBRACE 和 HEBON)。
1993 名 2006-09 年招募的 BRCA1/2 突变携带者女性。
采用加权 Cox 比例风险模型估计乳腺癌风险,该模型具有时间依赖性个体累积乳腺剂量,基于器官剂量的名义估计和自我报告诊断程序的频率。为纠正潜在的生存偏差,分析排除了在研究问卷完成前五年以上被诊断的携带者。
在携带 BRCA1/2 突变的女性中,30 岁之前任何暴露于诊断性辐射均与乳腺癌风险增加相关(风险比 1.90,95%置信区间 1.20 至 3.00),且存在剂量反应模式。累积剂量估计值<0.0020 Gy、≥0.0020-0.0065 Gy、≥0.0066-0.0173 Gy 和≥0.0174 Gy 的四分之一的风险分别为 1.63(0.96 至 2.77)、1.78(0.88 至 3.58)、1.75(0.72 至 4.25)和 3.84(1.67 至 8.79)。对不同类型诊断程序的分析显示,与无暴露相比,20 岁前和 30 岁前接受的 X 线片数量增加与风险增加相关。30 岁前的乳房 X 光检查史也与乳腺癌风险增加相关(风险比 1.43,0.85 至 2.40)。敏感性分析表明,这一发现不是由家族史指示的混杂因素引起的。
在这项针对 BRCA1/2 突变携带者的大型欧洲研究中,30 岁之前接受诊断性辐射与乳腺癌风险增加相关,其剂量水平远低于其他队列中发现的增加水平。该研究结果支持使用非电离辐射成像技术(如磁共振成像)作为 BRCA1/2 突变年轻女性监测的主要工具。